Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | TP53 | P04637 | 4/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6350981 | 0.87 | PDK1 (0.69) | MAPTALDH1A1LMNA | |
| SCHEMBL8569299 | 0.86 | MAPT (0.67) | MAPTALDH1A1LMNASMN1; SMN2TP53 | |
| SCHEMBL31344385 | 0.86 | MAPT (0.60) | MAPTALDH1A1LMNASMN1; SMN2TP53 | |
| SCHEMBL31000396 | 0.83 | MAPT (0.72) | MAPTALDH1A1LMNASMN1; SMN2TP53 | |
| SCHEMBL11827090 | 0.83 | MAPT (0.72) | MAPTALDH1A1LMNASMN1; SMN2TP53 | |
| SCHEMBL5740163 | 0.82 | TACR1 (0.59) | MAPTALDH1A1LMNASMN1; SMN2TP53 | |
| SCHEMBL11571840 | 0.81 | MAPT (0.86) | MAPTALDH1A1LMNASMN1; SMN2TP53 | |
| SCHEMBL27611956 | 0.81 | MAPT (0.72) | MAPTALDH1A1LMNASMN1; SMN2TP53 | |
| SCHEMBL12724369 | 0.81 | MAPT (0.56) | MAPTALDH1A1LMNASMN1; SMN2TP53 | |
| SCHEMBL31384417 | 0.81 | MAPT (0.67) | MAPTALDH1A1LMNASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101417964-A | Use of compounds for the elevation of pyruvate dehydrogenase activity | ASTRAZENECA AB (SE) | 2009-04-29 | — | — | CN | disclosed |
| US-6960688-B2 | Use of compounds for the elevation of pyruvate dehydrogenase activity | ASTRAZENECA AB (SE) | 2005-11-01 | — | — | US | disclosed |
| US-20040009979-A1 | Use of compounds for the elevation of pyruvate dehydrogenase activity | ZENECA LIMITED | 2004-01-15 | — | — | US | disclosed |
| US-6498275-B1 | Use of compounds for the elevation of pyruvate dehydrogenase activity | ASTRAZENECA AB (SE) | 2002-12-24 | — | — | US | disclosed |
| CN-1303281-A | Application of compound in enhancing activity of pyruvate dehydrogenase | ASTRA ZENECA LTD (SE) | 2001-07-11 | — | — | CN | disclosed |
| EP-1082110-A1 | USE OF COMPOUNDS FOR THE ELEVATION OF PYRUVATE DEHYDROGENASE ACTIVITY | AstraZeneca AB (SE) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999062506-A1 | USE OF COMPOUNDS FOR THE ELEVATION OF PYRUVATE DEHYDROGENASE ACTIVITY | ASTRAZENECA AB (SE) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009979-A1 | Use of compounds for the elevation of pyruvate dehydrogenase activity | PDHA1, PDK1, PDHB | MAPT 4122/4885ALDH1A1 15/4885LMNA 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.